Clinical characteristics and symptom duration among outpatients with COVID-19

Hunter, Krystal; Lee, Elizabeth Leilani; Hyman, Daniel; Bross, Peter; Alabd, Andrew; Betchen, Melanie; Terrigno, Vittorio; Talwar, Shikha; Ricketti, Daniel A.; Shenker, Bennett; Clyde, Thomas; Roberts, Brian W.

doi:10.1016/j.ajic.2021.10.039

Cited by 12 publications

(18 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It appears that symptoms differentiate the groups. Furthermore, Tenforde et al found that a prolonged symptom duration and disability are more common in hospitalized COVID-19 patients [81] , while the study of Lane et al demonstrated that the only factors associated with a prolonged duration of symptoms are the presence of lower respiratory symptoms or neurologic symptoms at disease onset [82] . Our findings verify the former study and are of particular importance for the elderly as they tend to be susceptible to a more severe course of COVID‐19 [83] .…”

Section: Discussionmentioning

confidence: 99%

Do selected lifestyle parameters affect the severity and symptoms of COVID-19 among elderly patients? The retrospective evaluation of individuals from the STOP-COVID registry of the PoLoCOV study

Kapusta

Chudzik

Kałuzińska

et al. 2023

Journal of Infection and Public Health

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Do selected lifestyle parameters affect the severity and symptoms of COVID-19 among elderly patients? The retrospective evaluation of individuals from the STOP-COVID registry of the PoLoCOV study

Kapusta

Chudzik

Kałuzińska

et al. 2023

Journal of Infection and Public Health

View full text Add to dashboard Cite

“…With more than 584 million confirmed cases and 6 million deaths reported to the WHO [ 1 ], the COVID-19 pandemic has affected millions of lives and a multitude of societies worldwide in the past few years. The majority of people infected with SARS-CoV-2 virus causing COVID-19 recover without treatment and return to normal life [ 2 ]. Although most symptoms resolve after a few weeks, some individuals experience symptoms that extend beyond 12 weeks.…”

Section: Introductionmentioning

confidence: 99%

Mental Fatigue, Activities of Daily Living, Sick Leave and Functional Status among Patients with Long COVID: A Cross-Sectional Study

Nielsen,

Leth,

Pedersen

et al. 2022

IJERPH

View full text Add to dashboard Cite

Studies suggest that persistent symptoms after COVID-19 (long COVID) influence functioning and activities of daily living (ADL). However, it is still uncertain how and to what extent. This study aimed to describe patient-reported mental fatigue, ADL problems, ADL ability, sick leave and functional status among patients with long COVID. In this cross-sectional study, 448 patients, ≥18 years old and referred to occupational therapy at a Danish Post-COVID-19 Clinic, were included. Mental fatigue was measured by the Mental Fatigue Scale, ADL problems and ability were measured by the Canadian Occupational Performance Measure, sick leave was self-reported and functional status was evaluated by the Post-COVID-19 Functional Status Scale. Mean age was 46.8 years, 73% of the patients were female, and 75% suffered from moderate to severe mental fatigue. The majority reported difficulties performing productive and leisure activities. The median performance and satisfaction scores were 4.8 and 3, respectively. In total, 56% of the patients were on sick leave, and 94% were referred to rehabilitation. A decrease in functional status was found between pre-COVID-19 and assessment. Conclusively, the patients were highly affected in their everyday life and had distinct rehabilitation needs. Future research is needed to address causalities and rehabilitation for this patient group.

show abstract

“…The corrected count matrices were combined through the Seurat 2 package and quality control was conducted. In brief, empty droplets were excluded using the EmptyDrops function in the DropletUtils 3 (v. 1.16.0) package in R at false discovery rate (FDR) < 0.01. Detailed information on the methods used in this study can be found in the Supporting Information.…”

Section: Methodsmentioning

confidence: 99%

“…As of December 2022, over 659 million confirmed cases of COVID‐19 and more than 6.7 million deaths had been reported globally 2 . Most patients presented with mild symptoms and recovered within 1–2 weeks 3 . However, certain individuals exhibited persistent symptoms that lasted for several weeks or months.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Integrative single‐cell transcriptome analysis provides new insights into post‐COVID‐19 pulmonary fibrosis and potential therapeutic targets

Kim,

Lim

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

The global COVID‐19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 virus has resulted in a significant number of patients experiencing persistent symptoms, including post‐COVID pulmonary fibrosis (PCPF). This study aimed to identify novel therapeutic targets for PCPF using single‐cell RNA‐sequencing data from lung tissues of COVID‐19 patients, idiopathic pulmonary fibrosis (IPF) patients, and a rat transforming growth factor beta‐1‐induced fibrosis model treated with antifibrotic drugs. Patients with COVID‐19 had lower alveolar macrophage counts than healthy controls, whereas patients with COVID‐19 and IPF presented with elevated monocyte‐derived macrophage counts. A comparative transcriptome analysis showed that macrophages play a crucial role in IPF and COVID‐19 development and progression, and fibrosis‐ and inflammation‐associated genes were upregulated in both conditions. Functional enrichment analysis revealed the upregulation of inflammation and proteolysis and the downregulation of ribosome biogenesis. Cholesterol efflux and glycolysis were augmented in both macrophage types. The study suggests that antifibrotic drugs may reverse critical lung fibrosis mediators in COVID‐19. The results help clarify the molecular mechanisms underlying pulmonary fibrosis in patients with severe COVID‐19 and IPF and highlight the potential efficacy of antifibrotic drugs in COVID‐19 therapy. Collectively, all these findings may have significant implications for the development of new treatment strategies for PCPF.

show abstract

Clinical characteristics and symptom duration among outpatients with COVID-19

Cited by 12 publications

References 59 publications

Do selected lifestyle parameters affect the severity and symptoms of COVID-19 among elderly patients? The retrospective evaluation of individuals from the STOP-COVID registry of the PoLoCOV study

Do selected lifestyle parameters affect the severity and symptoms of COVID-19 among elderly patients? The retrospective evaluation of individuals from the STOP-COVID registry of the PoLoCOV study

Mental Fatigue, Activities of Daily Living, Sick Leave and Functional Status among Patients with Long COVID: A Cross-Sectional Study

Integrative single‐cell transcriptome analysis provides new insights into post‐COVID‐19 pulmonary fibrosis and potential therapeutic targets

Contact Info

Product

Resources

About